Quantum Biopharma (QNTM) Accounts Payables (2018 - 2026)

Quantum Biopharma (QNTM) has 9 years of Accounts Payables data on file, last reported at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 52.37% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (up 52.37% YoY), and the FY2025 full-year result was $4.2 million, down 4.13% from the prior year.
• Accounts Payables fell to $3.6 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.9 million in Q1 2022 to a low of $2.4 million in Q1 2025.
• A 5-year average of $5.0 million and a median of $4.4 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 42.99% in 2023 and jumped 52.37% in 2026, its largest moves.
• Tracing QNTM's Accounts Payables over 5 years: stood at $7.1 million in 2022, then plunged by 47.92% to $3.7 million in 2023, then increased by 17.84% to $4.4 million in 2024, then slipped by 4.13% to $4.2 million in 2025, then dropped by 14.13% to $3.6 million in 2026.
• Business Quant data shows QNTM's Accounts Payables at $3.6 million in Q1 2026, $4.2 million in Q4 2025, and $4.1 million in Q3 2025.